Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
CRANBURY, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, today announced that it is scheduled to participate in the BIO CEO & Investor Conference at the New York Marriott Marquis in New York on Feb 10th-11th. President, Chief Executive Officer and Chief Financial Officer Lawrence A. Kenyon is scheduled to present on Tuesday, February 11th, at 10:15 a.m. ET. Interested parties can access the live audio webcast and archive for this presentation from the Investors Section of the Outlook website, www.outlooktherapeutics.com. Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Experience the best of biotech with two days of produ
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionGlobeNewswire
- Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]Seeking Alpha
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.MarketBeat
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]Seeking Alpha
OTLK
Earnings
- 2/14/24 - Beat
OTLK
Sec Filings
- 4/17/24 - Form SC
- 4/17/24 - Form 4
- 4/16/24 - Form D
- OTLK's page on the SEC website